ResMed 将来の成長

Future 基準チェック /26

ResMed利益と収益がそれぞれ年間11.3%と7.1%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に22.3% 11.2%なると予測されています。

主要情報

11.3%

収益成長率

11.2%

EPS成長率

Medical Equipment 収益成長	13.0%
収益成長率	7.1%
将来の株主資本利益率	22.3%
アナリストカバレッジ	Good
最終更新日	29 Jan 2025

今後の成長に関する最新情報

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 30

Recent updates

ResMed: Fully Valued With Medium-Term Challenges (Rating Downgrade)

Jan 24

ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 45% Above Its Share Price

Jan 13

ResMed (NYSE:RMD) Is Investing Its Capital With Increasing Efficiency

Jan 01

ResMed: Solid Execution, Pricey Valuation

Nov 25

Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why

Nov 13

We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

Nov 01

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Oct 20

ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price

Oct 08

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

Jul 02

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Apr 30

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 30

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

Apr 18

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Mar 22

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

Mar 10

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Feb 12

Why ResMed Is One Of My Top Picks In 2024

Jan 22

A First Look At ResMed

Jan 09

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

Oct 28

ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity

Sep 12

ResMed Has Become A Steal (Rating Upgrade)

Aug 10

Compound Your Wealth With ResMed

Jul 04

業績と収益の成長予測

NYSE:RMD - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2027	5,906	1,624	1,621	1,736	21
6/30/2026	5,502	1,476	1,515	1,596	25
6/30/2025	5,114	1,328	1,291	1,388	26
9/30/2024	4,807	1,113	1,347	1,441	N/A
6/30/2024	4,685	1,021	1,286	1,401	N/A
3/31/2024	4,584	958	1,071	1,199	N/A
12/31/2023	4,504	890	944	1,079	N/A
9/30/2023	4,375	907	792	935	N/A
6/30/2023	4,223	898	559	693	N/A
3/31/2023	4,016	863	408	535	N/A
12/31/2022	3,763	809	222	370	N/A
9/30/2022	3,624	786	305	461	N/A
6/30/2022	3,578	779	195	351	N/A
3/31/2022	3,539	779	344	498	N/A
12/31/2021	3,444	522	446	577	N/A
9/30/2021	3,349	500	397	527	N/A
6/30/2021	3,197	475	620	737	N/A
3/31/2021	3,091	457	733	840	N/A
12/31/2020	3,092	699	774	884	N/A
9/30/2020	3,028	680	684	784	N/A
6/30/2020	2,957	622	696	802	N/A
3/31/2020	2,892	513	505	614	N/A
12/31/2019	2,784	455	420	514	N/A
9/30/2019	2,699	419	487	573	N/A
6/30/2019	2,607	405	382	459	N/A
3/31/2019	2,525	446	374	447	N/A
12/31/2018	2,455	450	385	456	N/A
9/30/2018	2,405	335	390	459	N/A
6/30/2018	2,340	316	N/A	505	N/A
3/31/2018	2,273	307	N/A	516	N/A
12/31/2017	2,196	285	N/A	434	N/A
9/30/2017	2,125	352	N/A	422	N/A
6/30/2017	2,067	342	N/A	414	N/A
3/31/2017	2,029	324	N/A	417	N/A
12/31/2016	1,968	327	N/A	474	N/A
9/30/2016	1,893	346	N/A	510	N/A
6/30/2016	1,839	352	N/A	548	N/A
3/31/2016	1,773	357	N/A	505	N/A
12/31/2015	1,742	357	N/A	471	N/A
9/30/2015	1,710	353	N/A	421	N/A
6/30/2015	1,679	353	N/A	383	N/A
3/31/2015	1,641	353	N/A	399	N/A
12/31/2014	1,616	352	N/A	409	N/A
9/30/2014	1,578	348	N/A	387	N/A
6/30/2014	1,555	345	N/A	391	N/A
3/31/2014	1,554	331	N/A	400	N/A

アナリストによる今後の成長予測

収入対貯蓄率: RMDの予測収益成長率 (年間11.3% ) は貯蓄率 ( 2.6% ) を上回っています。

収益対市場: RMDの収益 ( 11.3% ) US市場 ( 15.1% ) よりも低い成長が予測されています。

高成長収益: RMDの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: RMDの収益 ( 7.1% ) US市場 ( 8.9% ) よりも低い成長が予測されています。

高い収益成長: RMDの収益 ( 7.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RMDの自己資本利益率は、3年後には高くなると予測されています ( 22.3 %)

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/01/30 17:11
終値	2025/01/30 00:00
収益	2024/09/30
年間収益	2024/06/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

ResMed Inc. 26 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。56

アナリスト	機関
John Hester	ANZ Equities Pty Limited
David Rescott	Baird
Michael Polark	Baird

ResMed 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 7.4% to US$258

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Price target increased by 7.3% to US$203

Price target decreased by 9.0% to US$195

Price target decreased by 7.7% to US$204

Price target decreased by 7.3% to US$214

Recent updates

ResMed Inc. Declares Quarterly Cash Dividend, Payable on March 20, 2025

ResMed: Fully Valued With Medium-Term Challenges (Rating Downgrade)

Price target increased by 7.4% to US$258

ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 45% Above Its Share Price

ResMed Inc. to Report Q2, 2025 Results on Jan 30, 2025

ResMed (NYSE:RMD) Is Investing Its Capital With Increasing Efficiency

Insufficient new directors

Chief Product Officer recently sold US$1.5m worth of stock

ResMed: Solid Execution, Pricey Valuation

Chief Product Officer notifies of intention to sell stock

Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why

CEO & Chairman notifies of intention to sell stock

We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

First quarter dividend of US$0.53 announced

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

ResMed Inc. Declares Quarterly Cash Dividend, Payable on December 12, 2024

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

CEO & Chairman notifies of intention to sell stock

ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price

ResMed Inc., Annual General Meeting, Nov 20, 2024

ResMed Unveils New Collection of Digital and Personalized Solutions Designed to Improve Sleep Health

Why ResMed's Rally Is Just Getting Started

ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors

CEO & Chairman notifies of intention to sell stock

ResMed Elects Christopher DelOrefice to the Board

CEO & Chairman notifies of intention to sell stock

Chief Product Officer recently sold US$10m worth of stock

ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Fourth quarter dividend increased to US$0.53

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

ResMed Inc. Declares Quarterly Cash Dividend, Payable on September 19, 2024

Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Returns On Capital Are A Standout For ResMed (NYSE:RMD)

CEO & Chairman notifies of intention to sell stock

ResMed Inc. to Report Q4, 2024 Results on Aug 01, 2024

ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

CEO & Chairman notifies of intention to sell stock

Now 22% undervalued

CEO & Chairman notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Third quarter dividend of US$0.48 announced

ResMed Inc. Declares Quarterly Cash Dividend, Payable on June 13, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

ResMed Inc. to Report Q3, 2024 Results on Apr 25, 2024

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

ResMed Inc. Announces the U.S. Launch of the AirFit F40

Founder recently sold US$5.0m worth of stock

Founder notifies of intention to sell stock

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Price target increased by 7.3% to US$203

Upcoming dividend of US$0.48 per share at 1.0% yield

Second quarter dividend of US$0.48 announced

Second quarter 2024 earnings released: EPS: US$1.42 (vs US$1.53 in 2Q 2023)

ResMed Inc. Declares Quarterly Cash Dividend, Payable on March 14, 2024

Why ResMed Is One Of My Top Picks In 2024

A First Look At ResMed

ResMed Secures Significant Victory in Patent Fight Against New York University

Resmed Inc. Announces Board Changes

Upcoming dividend of US$0.48 per share at 1.4% yield

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Resmed Inc. Announces Declared Quarterly Cash Dividend, Payable on December 14, 2023

Price target decreased by 9.0% to US$195

Price target decreased by 7.7% to US$204